This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Science-Based Medicine emphasized that Ventavia oversaw just three of the 153 clinical sites involved with Pfizer's trial and "a small fraction (~1,000 by the time the whistleblower was fired) of the trial's over ~44,000 subjects." On 10 October 2022, during a session of the European Parliament's Special Committee on the COVID-19 Pandemic, Pfizer executive Janine Small testified that the company had not evaluated the Pfizer–BioNTech COVID-19 vaccine for its ability to reduce transmission of the SARS-CoV-2 virus prior to its release to the general public. Dutch MEP Rob Roos described the admission as "scandalous". CEO Albert Bourla was slated to attend, but withdrew. Roos's statements in turn have been described as "misleading".
=== Taiwan === Ractopamine has been banned in Taiwan since 2006. In the summer of 2007, two US shipments including ractopamine-laced pork were rejected by Taiwan's health authorities, while the Taiwan government had been considering lifting the ban on such imports. This resulted in mass protests in the capital city, Taipei, by swine farmers insisting that the ban remain in place. Health Minister Hou Sheng-mou (侯勝茂) declared no lifting of the ban would occur unless related laws were amended. Although the use of ractopamine in livestock is still banned and enforced on the domestic industry, and the government has maintained a "zero tolerance" policy on pork imports that contain it, Taiwan's legislature amended the food safety act in August 2012 to allow the import of beef products containing up to a maximum residue level of 10 parts per billion of the additive. The remaining restrictions have been an obstacle to the two nations signing a free-trade agreement, and the Office of the United States Trade Representative (USTR)'s 2018 Trade Policy Agenda and 2017 Annual Report assert that these remaining restrictions "...are not based upon science..." and highlights their removal as among the main priorities for the US in its trade with Taiwan. However, Taiwan plans to ease the import restrictions on US pork commencing January 1, 2021
== External links == https://www.inf.ethz.ch/personal/gonnet/DarwinManual/node148.html https://web.expasy.org/docs/relnotes/relstat.html The most recent statistics from the Swiss-Prot protein knowledgebase. Section 6.1 contains the most up-to-date amino acid frequencies Sources of PAM matrices:
=== History of ideas === Brown, T.M. (1965). "Resource letter EEC-1 on the evolution of energy concepts from Galileo to Helmholtz". American Journal of Physics. 33 (10): 759–765. Bibcode:1965AmJPh..33..759B. doi:10.1119/1.1970980. Cardwell, D.S.L. (1971). From Watt to Clausius: The Rise of Thermodynamics in the Early Industrial Age. London: Heinemann. ISBN 978-0-435-54150-7. Guillen, M. (1999). Five Equations That Changed the World. New York: Abacus. ISBN 978-0-349-11064-6. Hiebert, E.N. (1981). Historical Roots of the Principle of Conservation of Energy. Madison, Wis.: Ayer Co Pub. ISBN 978-0-405-13880-5. Kuhn, T.S. (1957) "Energy conservation as an example of simultaneous discovery", in M. Clagett (ed.) Critical Problems in the History of Science pp.321–56 Sarton, G.; Joule, J. P.; Carnot, Sadi (1929). "The discovery of the law of conservation of energy". Isis. 13: 18–49. doi:10.1086/346430. S2CID 145585492. Smith, C. (1998). The Science of Energy: Cultural History of Energy Physics in Victorian Britain. London: Heinemann. ISBN 978-0-485-11431-7. Mach, E. (1872). History and Root of the Principles of the Conservation of Energy. Open Court Pub. Co., Illinois. Poincaré, H. (1905). Science and Hypothesis. Walter Scott Publishing Co. Ltd; Dover reprint, 1952. ISBN 978-0-486-60221-9. {{cite book}}: ISBN / Date incompatibility (help), Chapter 8, "Energy and Thermo-dynamics"
Sources: en.wikipedia.org
The birth of most Mexican drug cartels is traced to former Mexican Judicial Federal Police agent Miguel Ángel Félix Gallardo (Spanish: El Padrino, lit. 'The Godfather'), who founded the Guadalajara Cartel in 1980 and controlled most of the illegal drug trade in Mexico and the trafficking corridors across the Mexico–U.S. border along with Juan García Ábrego throughout the 1980s. He started by smuggling marijuana and opium into the U.S., and was the first Mexican drug chief to link up with Colombia's cocaine cartels in the 1980s. Through his connections, Félix Gallardo became the person at the forefront of the Medellín Cartel, which was run by Pablo Escobar. This was accomplished because Félix Gallardo had already established a marijuana trafficking infrastructure that stood ready to serve the Colombia-based cocaine traffickers. There were no other cartels at that time in Mexico. He oversaw operations with his cronies and the politicians who sold him protection. The Guadalajara Cartel suffered a major blow in 1985 when the group's co-founder Rafael Caro Quintero was captured, and later convicted, for the murder of DEA agent Enrique "Kiki" Camarena. Félix Gallardo then kept a low profile and in 1987 he moved with his family to Guadalajara. According to Peter Dale Scott, the Guadalajara Cartel prospered largely because it enjoyed the protection of the Dirección Federal de Seguridad (DFS), under its chief Miguel Nazar Haro. Félix Gallardo was arrested on April 8, 1989.
== Applications == TMU is miscible with a variety of organic compounds, including acids (e.g. acetic acid), bases (e.g. pyridine), and organic substances (e.g. ε-caprolactam, benzoic acid). TMU can also dissolve some inorganic salts such as silver nitrate and sodium iodide. TMU is often used in place of hexamethylphosphoramide (HMPA), which is a suspected carcinogen. TMU is suitable as a reaction medium for the polymerization of aromatic diacid chlorides (such as isophthalic acid) and aromatic diamines (such as 1,3-diaminobenzene (m-phenylenediamine)) to aramids such as poly (m-phenylene isophthalamide) (Nomex) The polymerization of 4-amino benzoic acid chloride hydrochloride in TMU provides isotropic viscous solutions of poly(p-benzamide) (PPB), which can be directly spun into fibers.
Phenotypes of overlap between Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy can be assumed. In the differential diagnosis of UCDM, even in patients without finger contractures, Bethlem myopathy could be considered.
Gabapentin, sold under the brand name Neurontin among others, is an anticonvulsant medication used to treat neuropathic pain (postherpetic neuralgia) and partial seizures of epilepsy. Gabapentin is a central nervous system (CNS) depressant and derivative of the inhibitory neurotransmitter, GABA. It is used for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain. It is moderately effective: about 30–40% of those given gabapentin for diabetic neuropathy or postherpetic neuralgia have a meaningful benefit. Gabapentin binds to α2δ subunits to modulate calcium channel function and neurotransmitter release, weakly affects glutamate signaling pathways, and does not act on GABA receptors. Sleepiness and dizziness are the most common side effects. Serious side effects include extreme sedation, respiratory depression and allergic reactions. In December 2008, the US Food and Drug Administration issued a class-wide warning for gabapentinoids for an increased risk of suicide. Approximately two years after this pronouncement, a pharmacoepidemiologic study was conducted that showed there was no outstanding difference in suicide attempt rates between pre- and post-gabapentin prescription groups. Gabapentin was first approved for use in the United Kingdom in 1993. It has been available as a generic medication in the United States since 2004. It is the first of several other drugs that are similar in structure and mechanism, called gabapentinoids.
On 3 January 2022, Hangman's Chair appeared on the Culturebox program on France 4. A Loner was released in February 2022. The band released the single "Who Wants To Die Old" alongside a music video directed by Oscar Bizarre, filmed before "Cold & Distant". A piece was finally performed by the pairing of Hangman's Chair and Regarde Les Hommes Tomber at the Roadburn Festival 2022 in Tilburg, Netherlands. On 23 June 2022, Arte Concert and Rolling Stone France teamed up to broadcast live the band's performance at Hellfest on YouTube. On 26 June, Hangman's Chair collaborated once again with the Nantes-based band Regarde Les Hommes Tomber for a concert on the Valley stage at Hellfest. The band performed at Les Francofolies in La Rochelle, France, and at other music festivals, and toured for five weeks with Paradise Lost. Hangman's Chair were ranked first in the "Best French Bands/Artists" category on the editorial board's year-end list of Guitar Part, a French monthly print magazine aimed at guitarists. Before embarking on a European tour with Igorrr, they presented a previously unreleased track, the six-minute single "Spleenwise", in March 2023. In 2023, Hangman's Chair were encouraged by their label to release a short, three-minute documentary titled A Portrait, directed by Kendy Ty, in which the band members recount their career and the A Loner era in a condensed and introspective way. For the documentary, the musicians returned to their neighbourhood, the school, and the playground where they grew up. In July 2023, the band performed at the Dour Festival in Belgium.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.